Diagnostic Kits/Paper: Difference between revisions
Jump to navigation
Jump to search
AClearwater (talk | contribs) |
AClearwater (talk | contribs) |
||
| Line 16: | Line 16: | ||
=== Overview of IP Landscape === | === Overview of IP Landscape === | ||
([http://cyber.law.harvard.edu/commonsbasedresearch/Overview_of_Economics_of_Intellectual_Property_in_Kits see overview]) | |||
==== Patent Protection ==== | ==== Patent Protection ==== | ||
===== Bayh-Dole ===== | ===== Bayh-Dole ===== | ||
| Line 25: | Line 25: | ||
=== Our Research Questions === | === Our Research Questions === | ||
== Our Methodology == | == Our Methodology == | ||
Revision as of 12:39, 3 December 2009
Are patents clogging the pipeline: The effects of intellectual property on commercialization and access to genetic diagnostics
(A Summary Paper of our Research to date)
By Carolina Rossini, Andrew Clearwater, and Mackenzie Cowell
Last Draft: December 3, 2009
Introduction
Description of the GDx Market
Defining Genetic Diagnostics
Brief History of GDx and Related Technology
- chemical patents at turn of century (see Palombi's work)
Overview of IP Landscape
Patent Protection
Bayh-Dole
Licensing
When IP Does and Does Not Work Effectively
Our Research Questions
Our Methodology
Forces affecting the GDx Industry
- Technical advances